A recently published study shows that inflammatory disease begins well before synovitis is seen on exam; a better understanding of what’s brewing before the storm could lead to the development of preventive therapies for RA.
High-resolution computed tomography shows evidence of ILD.
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
Prednisone or Methotrexate for Pulmonary Sarcoidosis?
The recently released PREDMETH study results indicate that methotrexate can be considered a real alternative to prednisone for patients with pulmonary sarcoidosis.
First ACR Guidance Statement for VEXAS Released
VEXAS is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. Given the variability in disease presentation & the limited number of studies to date, an international multidisciplinary panel of VEXAS experts was convened to provide guidance to healthcare providers on the condition’s management. We spoke to experts on the panel about the resulting guidance document.
Rethinking Lupus Nephritis: Are Current Approaches & Guidelines off Target?
A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.
Hydroxychloroquine Remains a Mainstay in Lupus Nephritis
New data: HCQ reduces risk of eGFR decline by 61–73% & slows kidney function loss. Early initiation is critical for renal health in lupus nephritis.
2024 ACR Guideline for the Screening, Treatment & Management of Lupus Nephritis
Review 28 recommendations covering proteinuria screening, biopsy indications & triple therapy regimens for lupus nephritis.
Obinutuzumab Aids Standard Therapy for Lupus Nephritis
Phase 3 REGENCY data: Obinutuzumab & standard therapy improve complete renal response rates in active lupus nephritis patients.
The ACR Releases New Lupus Nephritis Guideline
At a session of ACR Convergence 2024, speakers shared key elements of the new guideline on the screening, treatment and overall management of lupus nephritis in children and adults.1 This guideline attempts to balance the risks of medication side effects with the important goal of preserving kidney function. This is the ACR’s first lupus guideline…
Research Reviews: AURORA 2, & Urinary Biomarkers
AURORA 2 Voclosporin, a novel calcineurin inhibitor (CNI), is associated with a favorable metabolic profile with regard to lipids and glucose, and a predictable pharmacokinetic profile, resulting in no need for the therapeutic drug monitoring required of other CNIs. AURORA 2, a double-blind, phase 3 study, evaluated the longterm safety, tolerability and efficacy of voclosporin…
60-Day Comment Period Opens for FDA’s Draft Guidance on Biosimilars
The FDA has issued draft guidance recommending that all biosimilar medications be designated as interchangeable with their reference products upon initial FDA approval. A 60-day review and comment period of the draft guidance is now open, and the ACR will soon be submitting comments.
- 1
- 2
- 3
- …
- 250
- Next Page »